Answers are grounded in this paper and cite their sources.
We evaluated whether the interval from esophagectomy to postoperative adjuvant therapy (time to adjuvant therapy [TTAT]) was associated with disease-free survival (DFS), overall survival (OS), and adverse events after neoadjuvant treatment for esophageal cancer. This retrospective cohort included 177 patients who received 2–4 cycles of postoperative chemotherapy plus immune-checkpoint inhibition followed by maintenance immunotherapy after neoadjuvant treatment and esophagectomy. Eligibility required completion of the defined postoperative treatment sequence; patients receiving nonconforming regimens were excluded. Follow-up data were current through September 10, 2026. Patients were classified as TTAT ≤ 56 days ( n = 97) or > 56 days ( n = 80). Multivariable Cox models and propensity-score matching (PSM) were used to evaluate the association between TTAT and outcomes. Median follow-up was 42.3 months. There were 71 DFS events (28/97 versus 43/80) and 46 deaths (13/97 versus 33/80). Two-year DFS was 81.4% versus 70.0% (adjusted hazard ratio [HR] for > 56 versus ≤ 56 days, 2.31; 95% confidence interval [CI], 1.39–3.87; P = 0.001), and two-year OS was 91.8% versus 85.0% (adjusted HR, 3.09; 95% CI, 1.57–6.11; P = 0.001). After matching 64 patients per group, the corresponding HRs were 1.81 (95% CI, 1.00-3.26; P = 0.048) for DFS and 2.97 (95% CI, 1.33–6.65; P = 0.008) for OS. The overall incidence of recorded adverse events did not differ significantly between the two groups (72.2% versus 81.3%; P = 0.157). Among patients who received neoadjuvant treatment, esophagectomy, and a uniform postoperative chemoimmunotherapy followed by maintenance strategy, initiation of postoperative therapy within 56 days was independently associated with longer DFS and OS. The consistency of the multivariable, continuous-TTAT, and propensity-matched analyses indicates that TTAT carries prognostic information in this population. These findings support avoiding preventable postponement once postoperative recovery is adequate, but residual confounding and the retrospective design preclude causal interpretation or use of 56 days as a universal treatment threshold.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: